Antonio Bedalov, M.D., Ph.D.

FACULTY MEMBER

Antonio Bedalov, M.D., Ph.D.

Member
Clinical Research Division, Fred Hutch

Fax: 206.667.6519
Mail Stop: D2-190

Dr. Antonio Bedalov studies chromatin, the material that makes up the chromosomes of humans and other eukaryotes. He is learning how chromatin modifications influence important biological events within the cell’s nucleus and, in turn, how they affect development, aging and cancer formation. He also applies this knowledge to lay the groundwork for potential new therapies to treat cancer and other diseases. He has three main research areas. First, he studies how cells regulate the transcription and replication of repetitive DNA sequences. He also studies what happens when these processes break down. Second, Dr. Bedalov is developing potential cancer drugs called sirtuin inhibitors that affect a cell process for regulating gene expression. Dr. Bedalov and collaborator Dr. Julian Simon identified the first sirtuin inhibitors, including one with potent cancer-killing abilities in lab studies. Third, Dr. Bedalov studies X-chromosome inactivation, in which the cells of females silence one of their two X chromosomes. He is interested in manipulating this process as a therapy for Rett syndrome, a genetic disorder that results from a broken gene on one X chromosome. 

Other Appointments & Affiliations

Associate Professor, Medicine

Adjunct Associate Professor, Biochemistry

University of Washington

Education

1989, M.D. in Medicine, University of Zagreb School of Medicine, Zagreb, Croatia

1993, Ph.D. in Medical Sciences, University of Zagreb School of Medicine, Zagreb, Croatia

Find a Clinical Trial

For the Media

The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.

Email media@fredhutch.org or call 206.667.2210.